Diese Präsentation wurde erfolgreich gemeldet.
Die SlideShare-Präsentation wird heruntergeladen. ×

Pulmonary drug delivery system1

Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Wird geladen in …3
×

Hier ansehen

1 von 28 Anzeige

Weitere Verwandte Inhalte

Diashows für Sie (20)

Anzeige

Ähnlich wie Pulmonary drug delivery system1 (20)

Weitere von Sonam Gandhi (20)

Anzeige

Aktuellste (20)

Pulmonary drug delivery system1

  1. 1. PRESENTED BY: GANDHI SONAM MUKESHCHANDRA M.PHARM INDUSTRIAL PHARMACY 1
  2. 2. Pulmonary Drug Delivery system “Pulmonary drug delivery describes various systems,devices,formulations & method of delivery of drugs to the lung for the treatment of: Diseases of the respiratory tract. For systemic delivery via the drug.” Once the drug is administered they readily pass into the blood stream without the need of any enhancers 2
  3. 3. The pulmonary system consists of two regions 3
  4. 4. 4
  5. 5. Mechanism of drug absorption Drug diffusion through alveoli. Absorption through aqueous pores by carrier mediated transport. phagocytosis of insoluble particles allow absorption of compounds with low lipophilicity & or high molecular weight. 5
  6. 6. Inhaleables Advanced technology for pulmonary delivery is expanding a category of drugs called Inhaleables defined as respiratory & systemic therapies administered simply by inhaling. Advantages: It supply drugs into the blood stream directly. It provide a non-invasive method of drugs delivery. It furnish very rapid onset of action similar to I.V.route. 6
  7. 7. Aerosols Aerosol preparations are stable suspensions of solid material & liquid droplets in a gaseous medium. The drug delivery by aerosols is deposited in the airways by: Gravitational sedimentation Diffusion The term atomizer is used for a device that generates an aerosol & may be powdered by electrically/mechanically. 7
  8. 8. Advantages of an aerosol A dose can be removed without contamination of remaining material. The medication can be delivered directly to the affected area in a desired form such as spray or stable form. Irritation produced by mechanical application of topical medication is reduced or eliminated. Minimum contamination. Maximum stability. 8
  9. 9. Limitations of aerosols Poor patient compliance. Irritant activity . Increase bronco constriction. High cost of mfg. 9
  10. 10. Formulation of aerosol Aerosol product essentially consists of two components: Product concentrate Propellant Product concentrate consist of active ingredients or mixture of active ingredients Other necessary agents such as solvents, antioxidants & Surfactants. 10
  11. 11. Propellant Single or blend of various propellants are used. It is selected to give the desired vapour pressure, solubility & particle size. Propellants can be with active ingredients in many different ways producing products with varying characteristics. Depending on the type of aerosol system utilized,the pharmaceutical aerosol may be dispensed as fine mist,wet spray & semi-solid or solid. 11
  12. 12. Methods of Inhalation delivery •Aerosols •Pulmonary metered dose inhalers (PMDIs) •Dry powder inhalers (DPIs) •Nebulizers 12
  13. 13. 13
  14. 14. Metered dose inhalers(MDIs) Is a device that helps to deliver a specific amount of medication to the lungs. It is commonly used to treat asthma, chronic obstructive pulmonary disease(COPD). It is composed of 4 essential components. 1.The base formulation- drug ,propellant,excipients. 2.The container. 3.Metering valve . 4.The actuator (mouth piece). 14
  15. 15. Propellants: Commonly CFC propellants are used because of their low pulmonary toxicity , high chemical stability and purity and compatibility, Non-inflammable. But now a days the CFC propellants are replaced with Hydrofluoroalkanes(HFAs) as these CFC cause the ozone depletion effect. Examples: trichlorofluromethane dichlorodifluoromethane 1.2.dichlorotetrafluromethane. 15
  16. 16. Surfactants These are added to maintain the drug in dispersed state & promotes stability of formulation.  It is also lubricates the valve. Examples : oleic acid ,sorbitol. 16
  17. 17. Containers & valve Usually the container is made up of aluminum or glass. Glass containers are normally plastic coated or laminated to enhances their ability to ensure internal pressures of high magnitude. 17
  18. 18. Metering valves These are designed to release a fixed volume of product during each actuation. Usually valves volumes range from 25 to 100ml although larger volume are available. 18
  19. 19. DRY POWDER INHALERS This device dispenses a powder in a stream of inspired air. These are environmentally friend since they do not require CFC propellants for drug dispersion. Self medication is possible. 19
  20. 20. Two types of dry powder inhaler Passive dry powder inhaler Ex: Disc Inhaler, Easy haler Active dry powder inhaler Ex: spiors,prohaler. 20
  21. 21. Advantages Product and formulation stability High drug volume delivery per puff low susceptibility to microbial growth Applicable to both soluble and insoluble drugs Self medication is possible 21
  22. 22. Disadvantages : Hygroscopic powders have chances to particle growth. Accurate dose is required . 22
  23. 23. Nebulizer Nebulizers are those that aerosolize aqueous solutions of water-soluble drugs 0r suspensions & solvent-water based solutions of water- insoluble substances. Nebulizer have been successfully employed for drug delivery to the lung.  It is also used for local drug delivery to trachea for local anesthesia 23
  24. 24. There are two types of Nebulizer 1. Pneumatic Nebulizer :-It derives from pressurized gas source ex:- jet or hydro dynamic type 2. Electrical Nebulizer :-It operates from an electric source ex:-ultra sonic Nebulizer 24
  25. 25. Therapeutic application: For the treatment of asthma Pulmonary infections For chronic obstructive pulmonary disease Cardio vascular agents Blood glucose modifier Lung cancer Cystic fibrosis 25
  26. 26. List of marketed products Ventolin albuterol sulfate Asmol sulbutamol 26
  27. 27. REFERENCES 1.CONTROLLED DRUG DELIVERY CONCEPTS AND ADVANCES BY-S.P.VYAS & R.P.KHAR 2.MODERNPHARMACEUTICS FOUTH EDITION BY- BANKER & RHODES 3.ADVANCE IN CONTROLLED AND NOVEL DRUG DELIVERY BY-N.K. JAIN 4. Google.com 27
  28. 28. 28

×